TURALIO (Daiichi Sankyo)
(https://turalio.com) 📸 Data Snapshot: June 20, 2026Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
No reviews or testimonials are present, avoiding standard trust theatre traps; however, the review_count is 0 while bold medical claims are made. The site mentions being FDA-approved multiple times but fails to provide direct proof paths, such as links to the FDA approval letter or ClinicalTrials.gov registration, resulting in a proof_links_count of 0. While Prescribing Information is referenced in meta data, the lack of verifiable citations for the recurrence statistics (15% and 55%) in the clean text creates a minor evidence gap.
The ratio of verifiable evidence to assertions is high for a pharmaceutical site. The text provides specific numbers regarding tumor prevalence (10% to 20% for diffuse), typical patient age ranges (30 to 50 years), and tumor sizes (5 centimeters). While direct links to the source studies are missing from the scraped text, the specificity of the data points suggests high substance over vague marketing assertions.
Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.
🛡️ Trust Signals — reviews, proof links, trust-theatre check
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /en/ | 0 | 0 |
| /en/what-is-tgct/ | 0 | 0 |
| /en/treating-tgct/ | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"audience": "Patient",
"specialty": "Oncologic",
"url": "https://www.turalio.com/en",
"headline": "TURALIO® (pexidartinib), the first FDA-approved, oral treatment for TGCT.",
"description": "TURALIO® (pexidartinib), the first treatment indicated for symptomatic tenosynovial giant cell tumor (TGCT). See full Prescribing Info & Boxed Warning.",
"name": "TURALIO ® (pexidartinib) Patient Homepage",
"about": [
{
"@type": "MedicalCondition",
"name": [
"tenosynovial giant cell tumor",
"giant cell tumor of the tendon sheath",
"pigmented villonodular synovitis",
"TGCT",
"GCT-TS",
"PVNS",
"Symptomatic TGCT"
]
},
{
"@type": "MedicalTherapy",
"name": "TURALIO® (pexidartinib) Capsules",
"guideline": "TURALIO is a prescription medicine used to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS). It is not known if TURALIO is safe and effective in children.",
"adverseOutcome": [
"changes in blood liver tests",
"hair color changes",
"tiredness",
"increased cholesterol level in the blood",
"decreased white blood cells",
"decreased red blood cells",
"swelling in or around your eyes",
"rash",
"itching",
"hives",
"skin redness",
"acne",
"loss of taste or changes in the way things taste",
"decreased phosphate in your blood"
],
"seriousAdverseOutcome": [
"serious liver problems",
"liver failure",
"vanishing bile duct syndrome (VBDS)",
"hepatotoxicity",
"severe liver injury"
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
]
},
{
"@type": "Organization",
"@id": "https://daiichisankyo.us/#organization",
"name": "Daiichi Sankyo",
"alternateName": "DSI",
"url": "https://daiichisankyo.us/",
"sameAs": [
"https://www.linkedin.com/company/daiichi-sankyo/",
"https://x.com/DaiichiSankyoUS",
"https://www.youtube.com/@DaiichiSankyoUS",
"https://www.instagram.com/daiichisankyo_us/"
],
"logo": {
"@type": "ImageObject",
"url": "https://www.turalio.com/-/media/pexi_patient/images/logo/dsi-footer-logo.png",
"caption": "Daiichi Sankyo Logo"
}
}
]
}
/en/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"audience": "Patient",
"specialty": "Oncologic",
"url": "https://www.turalio.com/en",
"headline": "TURALIO® (pexidartinib), the first FDA-approved, oral treatment for TGCT.",
"description": "TURALIO® (pexidartinib), the first treatment indicated for symptomatic tenosynovial giant cell tumor (TGCT). See full Prescribing Info & Boxed Warning.",
"name": "TURALIO ® (pexidartinib) Patient Homepage",
"about": [
{
"@type": "MedicalCondition",
"name": [
"tenosynovial giant cell tumor",
"giant cell tumor of the tendon sheath",
"pigmented villonodular synovitis",
"TGCT",
"GCT-TS",
"PVNS",
"Symptomatic TGCT"
]
},
{
"@type": "MedicalTherapy",
"name": "TURALIO® (pexidartinib) Capsules",
"guideline": "TURALIO is a prescription medicine used to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS). It is not known if TURALIO is safe and effective in children.",
"adverseOutcome": [
"changes in blood liver tests",
"hair color changes",
"tiredness",
"increased cholesterol level in the blood",
"decreased white blood cells",
"decreased red blood cells",
"swelling in or around your eyes",
"rash",
"itching",
"hives",
"skin redness",
"acne",
"loss of taste or changes in the way things taste",
"decreased phosphate in your blood"
],
"seriousAdverseOutcome": [
"serious liver problems",
"liver failure",
"vanishing bile duct syndrome (VBDS)",
"hepatotoxicity",
"severe liver injury"
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
]
},
{
"@type": "Organization",
"@id": "https://daiichisankyo.us/#organization",
"name": "Daiichi Sankyo",
"alternateName": "DSI",
"url": "https://daiichisankyo.us/",
"sameAs": [
"https://www.linkedin.com/company/daiichi-sankyo/",
"https://x.com/DaiichiSankyoUS",
"https://www.youtube.com/@DaiichiSankyoUS",
"https://www.instagram.com/daiichisankyo_us/"
],
"logo": {
"@type": "ImageObject",
"url": "https://www.turalio.com/-/media/pexi_patient/images/logo/dsi-footer-logo.png",
"caption": "Daiichi Sankyo Logo"
}
}
]
}
This page presents a snapshot of public data from TURALIO (Daiichi Sankyo), captured on June 20, 2026, to show how machine logic reads Trust & Proof signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to TURALIO (Daiichi Sankyo): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://turalio.com to view the most current version of its content and see directly what this company is about and what it offers.